Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease. | ClinicLens
Patients with multivessel coronary artery disease often receive 12 months of dual antiplatelet therapy (DAPT) after stenting to reduce the risk of ischemic events. Whether extending DAPT beyond 12 months in event-free patients with multivessel disease provides a benefit is uncert
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.